Aetna Therapeutic Phlebotomy Coverage Update

inv-01: Medically necessary indications

Covered when ANY of the following indications are met:

Medically necessary indications: Erythrocytosis of undetermined etiology with hematocrit ≥55%; Hemochromatosis (including hereditary); Individuals receiving testosterone therapy with hematocrit ≥54% or hemoglobin ≥180 g/L; Non-alcoholic fatty liver disease (NAFLD) with hyperferritinemia; Non‑hereditary hemochromatosis/iron overload with elevated hepatic iron concentration; Polycythemia vera; Polycythemia secondary to arterio‑venous (A‑V) fistulae (for persons with hematocrit >60%); Polycythemia secondary to cor pulmonale (for persons with hematocrit >60%); Polycythemia secondary to cyanotic congenital heart disease (for persons with hematocrit >60%); Porphyria cutanea tarda; Sickle cell crisis.

inv-02: Experimental / Investigational indications

Not covered when used for any of the following indications:

Experimental/Investigational indications: Acute gouty arthritis; Chronic hepatitis C (adjunctive with interferon); Chronic urticaria; Common cold; Hemoglobin SC disease; Hyperferritinemia in alcoholic liver disease; Hypertension; Migraines; Myeloproliferative disorders without polycythemia vera; Progressive multiple sclerosis.

inv-03: Covered indications

Coverage supported when phlebotomy is used for established clinical indications and when condition-specific criteria are met

Accepted indications: Therapeutic phlebotomy for management of polycythemia vera; iron overload in hereditary or non‑hereditary hemochromatosis or secondary iron overload (including iron‑loading from supplements); porphyria cutanea tarda; symptomatic iron overload in NAFLD with hyperferritinemia; management in selected sickle‑cell disease contexts when used to control iron overload or as part of specific regimens.

Several references support phlebotomy as preferred treatment for hemochromatosis and as a core therapy for PV to control hematocrit.

inv-04: PV-specific criteria

Coverage/management considerations tied to risk status and monitoring

Polycythemia vera management: Low‑risk PV patients: serial phlebotomy and low‑dose aspirin to maintain hematocrit within target; High‑risk PV patients: phlebotomy plus cytoreductive therapy (prefer hydroxyurea).Hct <45% men, <42% women

Guideline‑based stratification by age and thrombosis history informs need for cytoreduction.

inv-05: TRT-related criteria

Testosterone therapy-associated polycythemia

TRT-associated polycythemia: Documented elevated hematocrit or hemoglobin attributable to testosterone therapy AND prior attempts at dose reduction or discontinuation (or evaluation for other causes) before initiating regular therapeutic phlebotomy.Hct >=54% or Hb >=180 g/L often used as action threshold

Monitor Hct 3–6 months after initiating TRT and periodically thereafter; consider phlebotomy if hematocrit cannot be controlled by dose adjustment or stopping therapy.

inv-06: Sickle cell disease notes

Sickle cell disease context

Sickle cell related uses: Phlebotomy has been used in combination with hydroxyurea in trials aiming to prevent secondary stroke recurrence and to manage iron overload; however, chronic transfusion remains the established therapy for primary and secondary stroke prevention in high‑risk children.

Randomized trials (STOP/STOP II/SWiTCH) demonstrated transfusion reduces stroke risk; hydroxyurea plus phlebotomy was not non‑inferior for secondary stroke prevention and iron overload management.

inv-07: Iron overload treatment criteria

Coverage aligns with guideline‑based indications and clinical evidence; phlebotomy is covered when indicated to reduce iron burden or control hematocrit.

Phlebotomy for iron overload (non‑anemic): Patient has documented iron overload (e.g., elevated hepatic iron concentration or elevated serum ferritin) AND patient does not have significant anemia that contraindicates phlebotomy AND clinician documents phlebotomy as treatment to reduce iron burden per guideline recommendation.LIC elevated or ferritin elevated per clinician/guideline assessment

Guidelines (AASLD/UpToDate) recommend phlebotomy for non‑anemic patients with iron overload; chelation preferred if anemia present.

inv-08: Erythrocytosis / polycythemia vera criteria

Coverage for erythrocytosis/polycythemia vera management when aiming to reduce thrombotic risk.

Phlebotomy for erythrocytosis: Phlebotomy to control hematocrit is indicated when hematocrit exceeds target levels or patient has thrombosis risk factors; recommended target hematocrit for PV is commonly <45% (men) to reduce thrombosis risk.Hct >45% (PV target <45%)

Secondary erythrocytosis should be managed by treating the underlying cause; routine phlebotomy is not recommended for all secondary causes.

inv-09: Gout-related phlebotomy considerations

Phlebotomy/blood‑letting therapy for gout has limited and variable evidence.

Phlebotomy for gout: Some small studies and meta‑analyses of blood‑letting approaches report reduced gout flares when near‑iron deficiency (NID) is maintained, but evidence is limited, heterogeneous, and not conclusive; clinical judgment required for individual patients.N/A

Studies report reduced flare frequency with NID maintenance, but the evidence base consists of small trials and observational reports.

The policy lists ICD-10-coded diagnoses for which therapeutic phlebotomy is not covered/considered experimental. Examples include B18.2 (chronic viral hepatitis C), G43.00–G43.919 (migraine), I10 (essential hypertension), J00 (acute nasopharyngitis / common cold), K70.0–K70.9 (alcoholic liver disease), K73.1–K73.9 (chronic hepatitis), L50.8 (other urticaria / chronic urticaria), and M10.00–M10.9 (gout). This list is illustrative of the ICD-10 codes identified in the coding section as not covered for the indications noted in the Clinical Policy Bulletin.

UpToDate topic reviews cited in the policy do not describe phlebotomy as a management option for hypertension or the common cold. The policy specifically notes that UpToDate reviews on resistant hypertension and general hypertension care make no mention of phlebotomy as a therapeutic approach, and migraine reviews similarly do not list phlebotomy as a treatment option.

An UpToDate review on the approach to suspected iron overload is cited as not mentioning therapeutic phlebotomy as a management option for hyperferritinemia related to alcoholic liver disease, indicating that phlebotomy is not routinely recommended for that specific context in the referenced guidance.

This Clinical Policy Bulletin is developed by Aetna to assist in administering plan benefits and does not constitute an offer of coverage or medical advice. It provides a general description of plan benefits and is not a contract; treating providers remain responsible for medical care and clinical decisions. The bulletin may be updated and is subject to change.

The policy identifies a set of conditions for which therapeutic phlebotomy is considered experimental or investigational / not medically necessary. Examples cited include acute gouty arthritis, chronic hepatitis C (as adjunctive therapy), chronic urticaria, common cold, hemoglobin SC disease, hyperferritinemia in alcoholic liver disease, hypertension, migraine, and progressive multiple sclerosis. Use of phlebotomy for these listed indications is characterized as lacking established effectiveness.

The policy summarizes the evidence for blood‑letting or phlebotomy in conditions such as migraine, chronic urticaria, common cold, and hypertension as limited and of low quality. Systematic reviews and small trials report possible benefits in some trials, but methodological limitations, heterogeneity, and risk of bias mean the evidence is preliminary and insufficient to support routine clinical use.

For secondary erythrocytosis, the policy states that routine phlebotomy is not recommended. Treatment should address the underlying cause (for example, smoking cessation, treating sleep apnea, or correcting hypoxia), and phlebotomy should be used selectively when clinically indicated rather than as routine management.

Coding: Applicable CPT/HCPCS and ICD-10 Codes

Covered CPT/HCPCS related to phlebotomy (when criteria met)mixedCovered

99195	Phlebotomy, therapeutic (separate procedure)
36415	Collection of venous blood by venipuncture
85014	Blood count; hematocrit (Hct)
85018	Blood count; hemoglobin (Hgb)
J1830	Injection interferon beta-1b, 0.25 mg
J9212	Injection, interferon alfacon-1, recombinant, 1 mcg
J9213	Interferon alfa-2A, recombinant, 3 million units
J9214	Interferon alfa-2B, recombinant, 1 million units
J9215	Interferon alfa-N3, (human leukocyte derived), 250,000 IU
J9216	Interferon gamma-1B, 3 million units

1–10 of 14

1/2

ICD-10 codes covered if selection criteria are metICD-10Covered

C94.00	Acute erythoid leukemia
C94.01	Acute erythoid leukemia
D45	Polycythemia vera
D57.00	HB-SS disease with crisis
D57.01	HB-SS disease with crisis
D57.02	HB-SS disease with crisis
D57.211	Sickle-cell/Hb-C disease with crisis
D57.219	Sickle-cell/Hb-C disease with crisis
D57.811	Other sickle-cell disorders with crisis
D57.819	Other sickle-cell disorders with crisis

1–10 of 20

1/2

ICD-10 codes listed as not covered/experimental for phlebotomy indicationsICD-10Not Covered

B18.2	Chronic viral hepatitis C
C92.10	Chronic myeloid leukemia, BCR/ABL-positive
C92.22	Chronic myeloid leukemia, BCR/ABL-negative
D47.3	Essential (hemorrhagic) thrombocythemia
D57.20	Sickle-cell/Hb-C disease without crisis
D75.81	Myelofibrosis
G35	Multiple sclerosis
G43.00	Migraine
G43.919	Migraine
I10	Essential (primary) hypertension

1–10 of 19

1/2

inv-20: Hematocrit threshold for erythrocytosis of undetermined etiology

Hematocrit thresholdHematocrit ≥55% for erythrocytosis of undetermined etiology

Applicable indicationUsed when erythrocytosis has no determined cause and Hct meets threshold

Source guidance contextBritish Society for Hematology and related reviews cite phlebotomy to control Hct and reduce thrombosis risk

inv-21: Hematocrit/Hemoglobin threshold for individuals on testosterone therapy

Action threshold (most actionable)Hematocrit ≥54% or Hemoglobin ≥180 g/L — consider dose reduction/stop of testosterone and/or therapeutic phlebotomy

Monitoring intervalMeasure hematocrit 3–6 months after initiating testosterone and then yearly

Management steps prior to phlebotomySeek other causes; reduce or stop TRT before considering phlebotomy if possible

inv-22: Ferritin targets for hemochromatosis — induction and maintenance targets

Induction target (most actionable)Reduce serum ferritin to 10–20 µg/L during induction phlebotomy

Maintenance targetMaintain serum ferritin ≤50 µg/L thereafter by periodic phlebotomy (guidelines also cite 50–100 µg/L range)

Typical induction scheduleRemoval of ~1 unit (450–500 mL) weekly until induction ferritin achieved

inv-23: Hematocrit/Hemoglobin thresholds — PV and TRT thresholds summarized

PV hematocrit goal (most actionable)Target Hct <45% in men and <42% in women to reduce thrombotic risk

TRT action thresholdConsider phlebotomy or dose adjustment if Hct ≥54% (Hb ≥180 g/L)

PV management noteLow-risk PV: serial phlebotomy + low-dose aspirin; high-risk PV: add cytoreductive therapy

inv-24: Hematocrit target for polycythemia vera — target Hct to reduce thrombosis risk

Target hematocrit to reduce thrombosis (most actionable)Maintain Hct <45% in polycythemia vera

Clinical rationaleHct control via phlebotomy reduces thrombotic risk; British Society for Hematology and UpToDate endorse this target

EscalationIf target not maintained, consider cytoreductive therapy for high-risk patients

inv-25: Deferasirox dosing comparison — reference dosing and pediatric phlebotomy schedule

Deferasirox reference doseDeferasirox starting dose 10 mg/kg/day (trial context)

Pediatric phlebotomy schedulePhlebotomy regimen in pediatric post-HSCT trial: 6 mL/kg every 2 weeks for 1 year

Comparative outcome noteLIC reductions observed with both deferasirox and phlebotomy; deferasirox showed greater LIC reduction in patients with baseline ferritin ≥1000 ng/mL

inv-26: Serum ferritin level noted — stratified subgroup threshold

Stratified ferritin subgroup (most actionable)>=1000 ng/mL — subgroup with greater LIC reduction on deferasirox versus phlebotomy

Outcome measuresSerum ferritin, non-transferrin-bound iron, and MRI-assessed LIC decreased with both therapies

Trial populationChildren post-HSCT with beta-thalassemia major in randomized 1-year trial

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior authorization — coding references

Prior authorization may be required for therapeutic phlebotomy depending on payer-specific rules and coding. Verify and obtain any required prior authorization before scheduling treatment when applicable.

Check payer prior authorization policy for CPT code 99195 and related venipuncture/lab codes (e.g., 36415, 85014, 85018).
Provide clinical documentation supporting indication (diagnosis, hematologic measurements, iron studies) when requesting authorization.

Note

Phlebotomy for testosterone-associated polycythemia

Phlebotomy can be considered for patients receiving testosterone therapy if hematocrit rises above guideline thresholds; reassess testosterone dose and evaluate for secondary causes before ongoing phlebotomy.

Measure hematocrit at 3–6 months after initiating testosterone and then annually.
Consider stopping or reducing testosterone if hematocrit ≥ 54% (Endocrine Society guidance) and consider phlebotomy if hematocrit cannot be controlled by dose adjustment and treatable causes excluded.

Prior Authorization

Prior authorization for therapeutic phlebotomy

Therapeutic phlebotomy is supported for treatment of iron overload and control of hematocrit when guideline-directed indications are met; prior authorization requests should include evidence of the indication and supporting lab results.

Common indications: hereditary or non-hereditary hemochromatosis with elevated ferritin/LIC, polycythemia vera for hematocrit control, porphyria cutanea tarda, select secondary erythrocytoses.
Include ferritin, hematocrit/hemoglobin, liver iron concentration (if available), prior therapies, and clinical indication in requests.

Documentation Required

Consider chelation before/alongside phlebotomy when appropriate

Consider iron chelation therapy before or alongside phlebotomy for patients who are anemic or intolerant of phlebotomy, or when chelation is otherwise clinically indicated.

Examples: post-transplant patients or those with transfusional iron overload where chelation may be used alone or with phlebotomy.
Document rationale when selecting chelation over or in addition to phlebotomy.

Denial Risk

Denial triggers — not covered diagnoses

Denials may be triggered when phlebotomy is requested for diagnoses that are listed as not covered for the procedure; ensure the diagnosis code(s) support a covered indication.

ICD-10 examples not covered for TP in this policy excerpt: chronic viral hepatitis C (B18.2); certain myeloproliferative disorders without PV (D47.3, D75.81); alcoholic liver disease (K70.*) when hyperferritinemia is attributable to alcohol-related liver injury; migraine (G43.*); essential hypertension (I10); acute nasopharyngitis (J00).
Do not use TP for conditions where phlebotomy is not an evidence-based treatment; provide alternative management documentation if indicated.

Note

PV hematocrit management implications

In polycythemia vera (PV) maintain target hematocrit to reduce thrombotic risk; failure to maintain targets with phlebotomy alone may require escalation to cytoreductive therapy.

Target hematocrit: <45% (general recommendation for PV; some sources specify <45% men and <42% women in certain contexts).
Low-risk PV: serial phlebotomy plus low-dose aspirin. High-risk PV: cytoreductive therapy (e.g., hydroxyurea or interferon) in addition to phlebotomy as needed.
If hematocrit remains above target despite adequate phlebotomy, document reason for escalation and prior treatment attempts.

Documentation Required

Procedure feasibility risks

Procedure feasibility risks may affect the ability to perform therapeutic phlebotomy and should be documented; anticipate and document venous access issues and potential patient distress or intolerance.

Document venous access difficulties, need for alternative access approaches, or repeated failed attempts.
Note patient intolerance (e.g., hypotension, vasovagal reactions) and any treatment modifications or cancellations.

Note

No explicit authorization or denial triggers present in excerpts

This policy excerpt does not state explicit prior authorization or automatic denial triggers in all segments; providers must consult current payer web resources or medical policy for up-to-date authorization requirements.

Absence of an explicit authorization statement here does not guarantee authorization is not required by the payer.
When in doubt, obtain prior authorization or pre-service review to reduce risk of claim denials.

Step Therapy

No step therapy requirements or algorithms specified

There are no step therapy requirements or defined algorithms stated in the provided excerpts for therapeutic phlebotomy; follow clinical guidelines and payer-specific clinical pathways if present elsewhere.

No step therapy or mandatory trial-of-therapy sequence specified in these excerpts.
If a payer requires step therapy, document prior treatments attempted and rationale for phlebotomy.

Note

Policy history and review dates documented

Policy history and review dates are documented; confirm effective date and next review for currency when applying this policy.

Effective date: 2003-01-17
Last review: 09/14/2023
Next review: 07/11/2024

Background and Definitions

Therapeutic phlebotomy is the controlled removal of a large volume of blood (commonly ~450–500 mL or about one pint) performed to reduce blood volume, red cell mass, or body iron stores. It is an established treatment for conditions such as hereditary hemochromatosis, polycythemia vera, porphyria cutanea tarda, and certain secondary polycythemias. For iron‑overload disorders, induction phlebotomy is typically performed periodically until serum ferritin reaches target induction levels, followed by maintenance phlebotomy to keep ferritin within guideline‑based targets.

inv-44: Definition — Therapeutic phlebotomy (therapeutic bleeding) concise definition

DefinitionControlled removal of a large volume (usually a pint or more) of blood to reduce red cell mass and iron stores

Primary purposesReduce blood volume, red cell mass, and iron stores

Typical indicationsUsed for hemochromatosis, polycythemia vera, porphyria cutanea tarda, and certain secondary polycythemias

inv-45: Definition — Polycythemia vera (PV) concise definition and management goals

Definition (most actionable)Polycythemia vera (PV): a myeloproliferative neoplasm characterized by erythrocytosis (often JAK2-driven); management focuses on reducing thrombotic risk using phlebotomy and low‑dose aspirin, adding cytoreduction for high‑risk patients

Risk stratificationHigh-risk defined by age >60 or prior thrombosis; low-risk managed with phlebotomy and aspirin

Diagnostic notePresence of JAK2 mutation supports diagnosis; absence plus normal/increased EPO excludes PV

inv-46: Definition — Therapeutic phlebotomy purpose to reduce red cell mass or iron stores

Primary purpose (most actionable)To reduce red cell mass (control hematocrit) or to remove excess iron stores depending on indication

Indication examplesUsed to control Hct in PV and to remove iron in hemochromatosis and iron‑overload states

MechanismProduces relative or absolute iron deficiency to lower hemoglobin/hematocrit and total body iron

inv-47: Definition — Near-iron deficiency (NID) maintenance target concept

Concept (most actionable)Near‑iron deficiency (NID): maintenance of body iron at the lowest level compatible with normal erythropoiesis without causing anemia

Clinical applicationTarget used in small studies of blood‑letting approaches (e.g., gout) to reduce symptoms by lowering iron stores

Monitoring implicationRequires serial ferritin/hematologic monitoring to avoid development of anemia

inv-48: Definition — Hepatic iron concentration (LIC) as MRI-assessed metric

Definition (most actionable)Hepatic iron concentration (LIC): MRI‑assessed metric quantifying liver iron (reported as mg Fe/g dry weight) used to assess iron overload and guide therapy

Role in decision makingElevated LIC supports phlebotomy in non‑anemic patients; reductions in LIC are an efficacy endpoint in trials

Reported measuresLIC decreases were reported in trials comparing chelation and phlebotomy; used alongside serum ferritin

OpenPayer

Therapeutic Phlebotomy

Coverage Criteria for Therapeutic Phlebotomy

Coding: Applicable CPT/HCPCS and ICD-10 Codes

Provider Actions, Documentation, and Authorization

Background and Definitions